Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ginkgol containing medicine composition for treating liver cancer

A technology for treating liver cancer and ginkgo phenol, which is applied in the directions of drug combination, active ingredients of hydroxyl compounds, medical raw materials derived from Ginkgo biloba, etc.

Inactive Publication Date: 2016-05-04
JIANGSU UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there is no literature report that Ginkgo biloba relieves cisplatin-induced immunosuppression

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ginkgol containing medicine composition for treating liver cancer
  • Ginkgol containing medicine composition for treating liver cancer
  • Ginkgol containing medicine composition for treating liver cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] This example illustrates the preparation of the active ingredient ginkgo biloba in anti-liver cancer drug preparations.

[0025] Experimental materials: Ginkgo biloba testa was collected from Zhenjiang City, Jiangsu Province, 200-300 mesh column chromatography silica gel, and other reagents were purchased from Shanghai Chemical Reagent Co., Ltd., analytically pure, without further treatment before use.

[0026] Experimental method: Weigh 100 g of dried Ginkgo biloba testa and pulverize it, ultrasonically extract 5 times the amount of petroleum ether three times, each time for 2 hours, combine the extracts, evaporate the solvent to obtain a petroleum ether extract. Dissolve the extract in a small amount of petroleum ether and apply it to a silica gel column (Φ3.2×40cm), elute with petroleum ether: ether: formic acid = 89:11:1 (v / v / v), and perform thin-layer chromatography Fluorescence was detected at 254nm, and the ginkgolic acid fraction was collected.

[0027] Take 1....

Embodiment 2

[0030] This example verifies the inhibitory effect of ginkgo biloba on the growth of HepG2 cells (human liver cancer cell line) in vitro

[0031] Experimental materials: Human liver cancer cell line HepG2 was purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences and preserved by Jiangsu University School of Medicine. Ginkgo biloba homologues were extracted from Ginkgo biloba testa in our laboratory (HPLC content >95%); DMEM cell culture medium and fetal bovine serum were purchased from Gibco; trypsin was purchased from Invitrogen; stored at -20°C; thiazolyl blue ( MTT), Giemsa dye; dimethyl sulfone (DMSO for short).

[0032] Experimental method: Take HepG2 cells in the logarithmic growth phase, digest with 0.25% trypsin, and dilute with DMEM complete culture solution to adjust to 5×10 4 Add 100 μl of cell suspension to each well of a 96-well plate, and use cell-free complete culture medium as the blank group. Place in a 37°C, 5% CO2 cell culture incubator....

Embodiment 3

[0038] This example verifies the synergistic effect of ginkgo biloba on the growth of HepG2 human liver cancer cells inhibited by cisplatin in vitro

[0039] Experimental materials: Human liver cancer cell line HepG2 was purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences and preserved by Jiangsu University School of Medicine. Ginkgo biloba homologues were extracted from Ginkgo biloba testa in our laboratory (HPLC content >95%); DMEM cell culture medium and fetal bovine serum were purchased from Gibco; trypsin was purchased from Invitrogen; stored at -20°C; thiazolyl blue ( MTT), Giemsa dye; dimethyl sulfone (DMSO for short), cisplatin (Sigma, product number 479306).

[0040] Experimental method: with embodiment 2. After the cells adhered to the wall, add a single cisplatin 10μg / ml and a mixture of cisplatin 10μg / ml and 5, 10, 20, 40, 80μg / ml of ginkgo biloba and culture for 24 hours, then add 5mg / ml of MTT solution to each well 10 μl, continue to incubate...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a ginkgol containing medicine composition for treating the liver cancer and relates to the technical field of medicinal compositions. Clinically-applied anti-tumor drugs cis-platinum and ginkgol are used in cooperation to form the anti-liver-cancer treatment medicinal composition. It is proved through experiments that ginkgol and cis-platinum are used in cooperation according to a certain proportion, the sensitivity of cis-platinum to liver cancer cells can be enhanced, and toxic and side effects of cis-platinum on the aspect of immunosuppression are reduced. Compared with chemotherapy on mousse through single cis-platinum, the living states of the mice treated by ginkgol and cis-platinum cooperatively is obviously improved, and the life cycle is prolonged.

Description

technical field [0001] The invention relates to the technical field of pharmaceutical compositions, in particular to a pharmaceutical composition for anti-liver cancer, in particular to using cisplatin and ginkgo biloba to treat liver cancer and obtain a series of combined drugs for anti-liver cancer. Background technique [0002] Liver cancer is one of the most common malignant tumors in my country, ranking second in the ranking of malignant tumor deaths. Currently, the treatment methods for liver cancer mainly include surgery, radiotherapy, chemotherapy, and immunotherapy. Among them, surgical treatment is still the best means of curative effect in various therapies. However, as clinically seen liver cancer patients have progressed to the middle and late stage when they are diagnosed, less than 25% of the liver cancer can be surgically resected; therefore, radiotherapy and chemotherapy are still the main means of clinical treatment of liver tumors. Cisplatin is a commonl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K33/24A61K31/05A61K36/16A61P35/00
CPCA61K33/24A61K31/05A61K36/16A61K2300/00
Inventor 杨小明李月英刘亚丽
Owner JIANGSU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com